Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

31P - Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma


09 Dec 2020


e-Poster Display Session


Nong Xu


Annals of Oncology (2020) 31 (suppl_7): S1428-S1440. 10.1016/annonc/annonc391


N. Xu1, B. Han2, S. Jiao3, C. Hu4, A. Mislang5

Author affiliations

  • 1 The First Affiliated Hospital of Zhejiang University Medical College, Hangzhou/CN
  • 2 Shanghai Chest Hospital, Shanghai/CN
  • 3 Chinese PLA General Hospital, Beijing/CN
  • 4 Shanghai Cancer center, Shanghai/CN
  • 5 Adelaide Cancer Centre, Kurralta Park/AU

Abstract 31P


Penpulimab is a humanized IgG1 mAb that blocks PD-1 binding to PD-L1, Penpulimab is engineered to eliminate FcγR binding and ADCC/ADCP completely, as compared to majority of marketed IgG4 PD-1 antibodies with ADCC/ADCP activity. Penpulimab demonstrats a slower PD-1 antigen binding off-rate than marketed PD-1 antibodies, which results in better cellular activity and higher receptor occupancy. Penpulimab also shows numerous contacts with N58 glycosylation on the BC loop of PD-1 which could be an advantage to facilitate interaction of PD-1 antibody. These structural differentiations offer more robust biological effect and enhance anti-tumor activity of Penpulimab.


This integrated safety analysis includes data from 422 patients (pts) treated with monotherapy or combination therapy of Penpulimab from 6 clinical trials: one dose-escalation and expansion study [AK105-101(in advanced solid tumor) treated with single dose of 1.0, 3.0, 10 mg/kg and 200mg Q2W] in Australia and 5 studies [AK105-201 (in R/R cHL), AK105-202 (in NPC) and AK105-204 (in advanced solid tumor) treated with 200mg Q2W monotherapy; AK105-203 (in HCC) treated with Penpulimab 200mg Q3W combined with Anlotinib 8mg d1-14 Q3W; AK105-301( in non-squamous NSCLC) treated with Penpulimab 200mg Q3W combined with chemotherapy] in China. In this analysis, immune-related adverse events (irAEs) of Penpulimab is based on suspected irAEs confirmed by medical review.


As of Jan 10 2020, a total of 422 patients (pts) [monotherapy: combo therapy= 329:93] received a median of 8 doses [1-52] of Penpulimab. Main types of tumor (≥10 pts) in this analysis include: R/R cHL (N=94), NPC (N=89), NSCLC (N=56), HCC (N=53), gastric/GEJ cancer (N=21), ovarian cancer (N=20), pancreatic cancer(N=11), esophageal cancer (N=11) and biliary duct carcinoma (N = 11). irAEs occurred in 23.0% of pts (G3 in 2.6%, no G4 or G5, serious in 0.7%, treatment discontinuation in 0.7%). Most common irAEs (≥1%) were hypothyroidism (9.2%), hyperthyroidism (4.3%), increased TSH (2.8%) and rash (2.4%).


Penpulimab demonstrates impressive safety profile with relatively lower incidence rate of ≥ Grade 3 immune-related adverse events.

Clinical trial identification

NCT03352531, NCT03722147, NCT03866967, NCT04172571, NCT04172506, NCT03866980.

Legal entity responsible for the study

Akeso, Inc.


Akeso, Inc.


Y. Xia, D. Xia, X. Jin, Z.M. Wang, B. Li: : Honoraria (self): Akeso, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.